Basic Research for Prevention of Interstitial Lung Diseases Induced by IL-18
IL-18所致间质性肺病预防的基础研究
基本信息
- 批准号:13670622
- 负责人:
- 金额:$ 2.3万
- 依托单位:
- 依托单位国家:日本
- 项目类别:Grant-in-Aid for Scientific Research (C)
- 财政年份:2001
- 资助国家:日本
- 起止时间:2001 至 2002
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
IL-18 was discovered as IFN-γ inducing factor (IGIF), and plays important roles in NK cell activation. IL-18 also induces proinflammatory cytokines, chemokines, T helper 2 (Th2) cytokine (e.g. IL-4, IL-13), IgE and IgG1 production. The combination of IL-18 plus IL-2 or IL-12 upregulates IFN-γ gene expression, NK cytotoxicity, and has synergistic anti-tumor activity in vitro and in vitro. Here we report that daily administration of IL-18 with IL-2, but not IL-18 or IL-2 alone induces lethal lung injury in normal mice, but not IL-18Rα (IL-1R related protein) deficient (-/-) mice. Marked interstitial infiltration of lymphocytes, composed mainly of NK cells was found in the lungs of IL-18/IL-2-treated mice. Increased cytokine and chemokine levels were observed in the sera and lungs of IL-18/IL-2-treated mice. Administration of IL-I8/TL-2 was also lethal to mice treated with a metalloproteinase inhibitor, which inhibited TNF-α and FasL release. While IFN-γ (-/-) mice were partially resistant to the treatment, IL-4 (-/-), IL-4/IL-13 (-/-) and Stat6 (-/-) mice were sensitive to the IL-18/IL-2 indicating these genes were not involved in the host response. The lethal effect by IL-I8/IL-2 was completely eliminated in SCID mice pretreated with anti-asialo-GM1 Ab and normal mice pretreated with anti-NK1.1, but not anti-CD4 or anti-CD8 mAb. These results suggest that specific cytokines, chemokines and NK cells are involved in the pathogenesis of interstitial pneumonia. These results suggest that the clinical use of this interleukin may result in unexpected physiological consequences.
IL-18作为IFN-γ诱导因子(IGIF)被发现,在NK细胞活化中起重要作用。IL-18还诱导促炎细胞因子、趋化因子、T辅助细胞2(Th 2)细胞因子(例如IL-4、IL-13)、IgE和IgG 1产生。IL-18加IL-2或IL-12的组合上调IFN-γ基因表达、NK细胞毒性,并且在体外和体外具有协同抗肿瘤活性。我们在此报道了IL-18与IL-2联合给药,而不是IL-18或IL-2单独给药,在正常小鼠中诱导致死性肺损伤,但在IL-18 R α(IL-1 R相关蛋白)缺陷(-/-)小鼠中不诱导致死性肺损伤。在IL-18/IL-2处理的小鼠的肺中发现了主要由NK细胞组成的淋巴细胞的显著间质浸润。在IL-18/IL-2处理的小鼠的血清和肺中观察到增加的细胞因子和趋化因子水平。IL-18/TL-2对金属蛋白酶抑制剂处理的小鼠也具有致死性,其抑制TNF-α和FasL的释放。虽然IFN-γ(-/-)小鼠对治疗部分耐受,但IL-4(-/-)、IL-4/IL-13(-/-)和Stat 6(-/-)小鼠对IL-18/IL-2敏感,表明这些基因不参与宿主应答。在用抗去唾液酸GM 1抗体预处理的SCID小鼠和用抗NK 1.1抗体预处理的正常小鼠中,IL-18/IL-2的致死作用被完全消除,但抗CD 4或抗CD 8 mAb不能。这些结果表明,特异性细胞因子、趋化因子和NK细胞参与了间质性肺炎的发病机制。这些结果表明,这种白细胞介素的临床使用可能会导致意想不到的生理后果。
项目成果
期刊论文数量(27)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
Suzuki, A., T. Hanada, K. Mitsuyama, T. Yoshida, S. Kamizono, T. Hoshino, M. Kubo, A. Yamashita, M. Okabe, K. Takeda, S. Akira, S. Matsumoto, A. Toyonaga, M. Sata, and A. Yoshimura: "Cis3/socs3/ssi3 plays a negative regulatory role in stat3 activation and
铃木,A.,T. Hanada,K. Mitsuyama,T. Yoshida,S. Kamizono,T. Hoshino,M. Kubo,A. Yamashita,M. Okabe,K. Takeda,S. Akira,S. Matsumoto,A
- DOI:
- 发表时间:
- 期刊:
- 影响因子:0
- 作者:
- 通讯作者:
Lee SJ, et al.: "Both E6 and E7 oncoproteins of human papillomavirus 16 inhibit IL-18-induced IFN-gamma production in human peripheral blood mononuclear and NK cells"Journal of Immunology. 166. 497-504 (2001)
Lee SJ 等人:“人乳头瘤病毒 16 的 E6 和 E7 癌蛋白均抑制人外周血单核细胞和 NK 细胞中 IL-18 诱导的 IFN-γ 产生”《免疫学杂志》。
- DOI:
- 发表时间:
- 期刊:
- 影响因子:0
- 作者:
- 通讯作者:
Suzuki A, et al.: "Cis3/socs3/ssi3 plays a negative regulatory role in stat3 activation and intestinal inflammation"Journal Exp Medicine. 193. 471-482 (2001)
Suzuki A 等人:“Cis3/socs3/ssi3 在 stat3 激活和肠道炎症中发挥负调节作用”Journal Exp Medicine。
- DOI:
- 发表时间:
- 期刊:
- 影响因子:0
- 作者:
- 通讯作者:
Kawase, Y., T. Hoshino, K. Yokota, A. Kuzuhara, Y. Kirii, E. Nishiwaki, Y. Maeda, J. Takeda, M. Okamoto, T. Imaizumi, S. Kato, H. Aizawa, and K. Yoshino: "Exacerbated and prolonged allergic and non-allergic inflammatory cutaneous reaction in mice with tar
Kawase, Y.、T. Hoshino、K. Yokota、A. Kuzuhara、Y. Kirii、E. Nishiwaki、Y. Maeda、J. Takeda、M. Okamoto、T. Imaizumi、S. Kato、H. Aizawa 和
- DOI:
- 发表时间:
- 期刊:
- 影响因子:0
- 作者:
- 通讯作者:
Kawase, Y., T. Hoshino, K. Yokota, A. Kuzuhara, M. Nakamura, Y. Maeda, E. Nishiwaki, M. Zenmyo, H. Aizawa, and K. Yoshino: "Bone Malformations in IL-18 Transgenic Mice"J. Bone Mineral Res.. In press.
Kawase, Y.、T. Hoshino、K. Yokota、A. Kuzuhara、M. Nakamura、Y. Maeda、E. Nishiwaki、M. Zenmyo、H. Aizawa 和 K. Yoshino:“IL-18 转基因中的骨畸形
- DOI:
- 发表时间:
- 期刊:
- 影响因子:0
- 作者:
- 通讯作者:
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
HOSHINO Tomoaki其他文献
HOSHINO Tomoaki的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('HOSHINO Tomoaki', 18)}}的其他基金
Study for roles of inflammatory cells and cytokines in asthma death, COPD and mouse pulmonary disease models
炎症细胞和细胞因子在哮喘死亡、慢性阻塞性肺病和小鼠肺部疾病模型中的作用研究
- 批准号:
21590977 - 财政年份:2009
- 资助金额:
$ 2.3万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Study for roles of IL-18 in interstitial lung diseases and lung remodeling
IL-18在间质性肺疾病和肺重塑中的作用研究
- 批准号:
15390261 - 财政年份:2003
- 资助金额:
$ 2.3万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Molecular immunological analysis for IgE production and a unique NK cell population producing type 2 cytokine, IL-13
IgE 产生和产生 2 型细胞因子 IL-13 的独特 NK 细胞群的分子免疫学分析
- 批准号:
11670468 - 财政年份:1999
- 资助金额:
$ 2.3万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
相似海外基金
Knockdown of AdipoR2 Compromises Adiponectin’s Anti-inflammatory Actions by Mainly Promoting a Pro-inflammatory Chemokine and Cytokine Secretory Profile in THP-1 Macrophages
AdipoR2 的敲低主要通过促进 THP-1 巨噬细胞中促炎趋化因子和细胞因子的分泌特征来损害脂联素的抗炎作用
- 批准号:
493138 - 财政年份:2023
- 资助金额:
$ 2.3万 - 项目类别:
MicroRNA-15a/16-mediated cytokine/chemokine reprogramming in Kupffer cells prevents the development of hepatocellular carcinoma
MicroRNA-15a/16 介导的库普弗细胞细胞因子/趋化因子重编程可预防肝细胞癌的发展
- 批准号:
10518314 - 财政年份:2022
- 资助金额:
$ 2.3万 - 项目类别:
MicroRNA-15a/16-mediated cytokine/chemokine reprogramming in Kupffer cells prevents the development of hepatocellular carcinoma
MicroRNA-15a/16 介导的库普弗细胞细胞因子/趋化因子重编程可预防肝细胞癌的发展
- 批准号:
10688153 - 财政年份:2022
- 资助金额:
$ 2.3万 - 项目类别:
Determination of disease characteristics of Castleman's disease and Rheumatoid arthritis using serum cytokine and chemokine patterns.
使用血清细胞因子和趋化因子模式确定卡斯尔曼病和类风湿性关节炎的疾病特征。
- 批准号:
20K10460 - 财政年份:2020
- 资助金额:
$ 2.3万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Regulation of Cytokine/Chemokine Production and Anti-inflammatory therapy by Natural Products
天然产物对细胞因子/趋化因子产生的调节和抗炎治疗
- 批准号:
16K09306 - 财政年份:2016
- 资助金额:
$ 2.3万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
A role of TRPV6 calcium channel inhibition on cytokine and chemokine production by epithelial cells
TRPV6钙通道抑制对上皮细胞细胞因子和趋化因子产生的作用
- 批准号:
485506-2015 - 财政年份:2015
- 资助金额:
$ 2.3万 - 项目类别:
Engage Grants Program
Comprehensive analysis of cytokine and chemokine in prostatic hypertrophy with non-bacterial chronic inflammation
前列腺肥大伴非细菌性慢性炎症中细胞因子和趋化因子的综合分析
- 批准号:
26462444 - 财政年份:2014
- 资助金额:
$ 2.3万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Spatial optimization of T cell activation at inflamed sites via cytokine/chemokine-dependent cellular clustering
通过细胞因子/趋化因子依赖性细胞聚类对炎症部位 T 细胞激活进行空间优化
- 批准号:
10241369 - 财政年份:2014
- 资助金额:
$ 2.3万 - 项目类别:
Spatial optimization of T cell activation at inflamed sites via cytokine/chemokine-dependent cellular clustering
通过细胞因子/趋化因子依赖性细胞聚类对炎症部位 T 细胞激活进行空间优化
- 批准号:
10477325 - 财政年份:2014
- 资助金额:
$ 2.3万 - 项目类别:
Defining extrinsic and intrinsic factors that differentially regulate migratory properties, cytokine/chemokine production, cytolytic function of NK cells
定义差异调节 NK 细胞迁移特性、细胞因子/趋化因子产生、溶细胞功能的外在和内在因素
- 批准号:
RGPIN-2014-04775 - 财政年份:2014
- 资助金额:
$ 2.3万 - 项目类别:
Discovery Grants Program - Individual